Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
January 26, 2022 16:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities
January 26, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Company advancing diversified portfolio focused on areas of significant unmet medical need– Supported by solid financial position with cash to fund operations beyond 2023 TORONTO,...
Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
January 20, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Live video webcast presentation on Wednesday, January 26th at 9:00 AM ET CHARLESTON, S.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the...
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
January 05, 2022 08:36 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer
December 23, 2021 16:05 ET
|
Aeterna Zentaris Inc
– Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors TORONTO, ONTARIO, Dec. 23, 2021 (GLOBE NEWSWIRE) --...
Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates
November 04, 2021 16:05 ET
|
Aeterna Zentaris Inc
– Company continues to build strong developmental pipeline – Supported by solid cash position TORONTO, ONTARIO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS)...
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021 08:00 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a...
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
August 04, 2021 16:05 ET
|
Aeterna Zentaris Inc
– Company continues to advance clinical and preclinical programs with its diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need – Strong...
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
July 29, 2021 08:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
June 07, 2021 08:05 ET
|
Aeterna Zentaris Inc
– Dr. Levy is a well-established neuroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders – Company continues to advance development of...